The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

Figure 4

Cost-effectiveness diagram. EpoB is dominated by CERA since it is more costly and less effective.